- Global Pharma News & Resources

ALTURiX CEYESTO® Granted Expanded UK Indication By the MHRA

Issued: London, Tuesday 22nd November 2022

Announced today, ALTURiX - a rapidly-growing British pharmaceutical company - has been granted an expanded indication in the UK for CEYESTO® 3mg Tablets, an immediate release form of melatonin.

CEYESTO® has been available in the UK for over a year for the short term treatment of jet lag in adults, and has now also been approved by the MHRA for Insomnia in children and adolescents aged 6-17 years with ADHD, where sleep hygiene measures have been insufficient.

Commenting on the approval, Lak Sahota, Founder and Director at ALTURiX said, 

“The treatment of insomnia in young patients with ADHD is complex.  We are delighted that we can help by increasing the number of licensed treatment options available to prescribers and patients. Melatonin prescribing costs continue to increase and potentially we are able to help the NHS save over £20m on its annual melatonin prescribing in this age group.  As part of our Medicines Value Programme, Ceyesto® is a product at the very heart of our approach at ALTURiX, offering value to the NHS at fair and appropriate prices.”  

Dr Hugh Selsick, Consultant in Sleep Medicine at the Sleep Disorders Centre at Guy’s and St Thomas commenting on this launch said, “Sleep is essential to good physical and mental health. In children and adolescents with ADHD it is also important for academic performance. So having another option for treating insomnia in these patients has the potential to improve children's lives and long-term outcomes. It is particularly encouraging that this treatment is licensed and being made available by ALTURiX at a low cost which should also help remove the barriers to making it available for those children who may benefit from it.”

Founded in 2020 following the acquisition of two family-owned pharmaceutical companies, ALTURiX has a portfolio of well-known medicines which are prescribed widely by the NHS.  Over the last five years the company has accelerated its growth through a programme of new product acquisitions, and subsequent market introductions. 

The clear mission set out by the ALTURiX founders is to reliably provide high quality branded medicines at sensible prices, as embodied by the company’s Medicines Value Programme.  

The company fundamentally believes that improving the value a medicine brings can take many different forms. Whilst it is tempting to immediately think of saving money, ALTURiX believe that the best value can be delivered when their products provide benefits to the patient, to the prescriber, and to the NHS.

Editor Details

Related Links

Last Updated: 22-Nov-2022